A client is receiving irinotecan as treatment for metastatic colorectal cancer. Which symptom should indicate to you that the client has a UDP- glucuronosyltransferase deficiency?

Question

Quizplus · Accepted Answer

UDP-glucuronosyltransferase is involved in the metabolism of irinotecan,
a chemotherapeutic drug that is used in the treatment of metastatic colorectal cancer. Variations in the gene that codes for this enzyme can influence the client's ability to break down the major active metabolite in irinotecan. The inability to degrade the metabolite can lead to increased blood concentrations and increased risk of experiencing severe diarrhea. Muscle cramps, rapid respirations, and low blood pressure are not symptoms that indicate a deficiency of UDP-glucuronosyltransferase.

A Client Is Receiving Irinotecan as Treatment for Metastatic Colorectal